Indeed, this is verified by the observation that cultured podocytes treated with serum from FSGS patients have low activity of the ASMase enzyme in addition to decreased SMPDL3b expression levels. The gene discussed is SMPDL3B; the disease is focal segmental glomerulosclerosis.